References
- Larsen JP, Worm-Peterson J, Siden A, et al. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003;10:137-46
- Nissinen H, Ellmen J, Leinonen M, et al. Five-year efficacy of levodopa, DDCI and entacapone in Parkinson’s disease patients. Mov Disord 2006;21:S468
- Fung V on behalf of the Movement Disorder Society of Australia Clinical Research, Trials Group (MDSCRTG) & QUEST-AP Study Group. A randomized, double-blind study to compare the effect on quality of life of levodopa/carbidopa/entacapone (Stalevo) with levodopa/carbidopa in patients with Parkinson's disease with no or minimal, non-disabling motor fluctuations. Mov Disord 2006;21:S446
- Olanow CW, Obeso J, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
- Grosset K, Bone I, Grosset D. Suboptimal medication adherence in Parkinson’s disease. Mov Disord 2005;20:1502-7
- Stocchi F. The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opin Pharmacother 2006;7:1399-407
- Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004;82:935-9
- Stalevo prescribing information. Available at: www.pharma.us.novartis.com/product/pi/pdf/stalevo.pdf. Last accessed: September 2009
- Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 2005;53:197-202
- Adamson DM, Stella Chang S, Hansen LG. Health Research Data for the Real World: The MarketScan Databases. Stamford, CT: Thomson Healthcare, 2006
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
- McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. London: Chapman and Hall, 1989
- Pasta DJ, Cisternas MG. Estimating Standard Errors for CLASS Variables in Generalized Linear Models Using PROC IML. SAS® Users Group International (SUGI 28) Proceedings. March 30 - April 2, 2003. Seattle, Washington. Available at http://www2.sas.com/proceedings/sugi28/Proceed.pdf. Last accessed: September 2009
- Ghali WA, Quan H, Brant R, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494-7
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
- Lewis CC, Fiscella RG, Kosty T. Need for greater scrutiny of days supply values in DACON calculations. J Manag Care Pharm 2004;10:172-3
- Grosset KA, Bone I, Reid JL, et al. Measuring therapy adherence in Parkinson’s disease: a comparison of methods. J Neurol Neurosurg Psychiatry 2006;77:249-51
- Wang Y, Wu D, Wang Y, et al. A survey on adherence to secondary ischemic stroke prevention. Neurol Res 2006;28:16-20
- Holley JL, DeVore CC. Why all prescribed medications are not taken: results from a survey of chronic dialysis patients. Adv Perit Dial 2006;22:162-6
- Gleason PP, Starner CI, Gunderson BW, et al. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm 2009;15:648-58